You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1504-ESGO Tamoxifen-megestrol acetate combination hormonal therapy is an effective fertility-sparing treatment in early-stage endometrial cancer patients who have failed progestin only hormonal therapy

Alerts

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-1504-ESGO Tamoxifen-megestrol acetate combination hormonal therapy is an effective fertility-sparing treatment in early-stage endometrial cancer patients who have failed progestin only hormonal therapy
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address